Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hiporfin-PDT versus ALA-PDT for extramammary Paget's disease
ChiCTR1900024965Phase 4Recruiting
- Sponsor
- Shanghai Skin Disease Hospital
- Start
- Aug 2019
- Modality
- Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of hemoporfin and 5-aminolevulinic acid in extramammary Paget disease (EMPD) (2 arms), sponsored by Shanghai Skin Disease Hospital. Primary endpoints: Change in lesion area one month after treatment and Change in maximum depth of lesion infiltration one month after treatment. Started Aug 2019; status: recruiting.
02
Drugs
hemoporfin5-aminolevulinic acid
03
Conditions
extramammary Paget disease (EMPD)
Beyond the preview
Go deeper on ChiCTR1900024965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024965.